GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Shiller PE Ratio

Paratek Pharmaceuticals (FRA:N4CN) Shiller PE Ratio : (As of Jun. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Paratek Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Paratek Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Shiller PE Ratio Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Paratek Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Paratek Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Shiller PE Ratio falls into.



Paratek Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Paratek Pharmaceuticals's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Paratek Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.231/128.7287*128.7287
=-0.231

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -2.244 98.790 -2.924
201312 -2.540 98.326 -3.325
201403 -1.301 99.695 -1.680
201406 -1.590 100.560 -2.035
201409 -4.004 100.428 -5.132
201412 -0.305 99.070 -0.396
201503 -0.684 99.621 -0.884
201506 -0.855 100.684 -1.093
201509 -1.185 100.392 -1.519
201512 -1.102 99.792 -1.422
201603 -1.598 100.470 -2.047
201606 -1.504 101.688 -1.904
201609 -0.927 101.861 -1.172
201612 -1.062 101.863 -1.342
201703 -1.066 102.862 -1.334
201706 -0.587 103.349 -0.731
201709 -0.646 104.136 -0.799
201712 -0.659 104.011 -0.816
201803 -0.738 105.290 -0.902
201806 -0.805 106.317 -0.975
201809 -0.866 106.507 -1.047
201812 -0.624 105.998 -0.758
201903 -0.974 107.251 -1.169
201906 -0.903 108.070 -1.076
201909 -0.908 108.329 -1.079
201912 -0.729 108.420 -0.866
202003 -0.597 108.902 -0.706
202006 -0.471 108.767 -0.557
202009 -0.391 109.815 -0.458
202012 -0.444 109.897 -0.520
202103 -0.328 111.754 -0.378
202106 0.166 114.631 0.186
202109 -0.315 115.734 -0.350
202112 -0.584 117.630 -0.639
202203 -0.318 121.301 -0.337
202206 -0.312 125.017 -0.321
202209 -0.384 125.227 -0.395
202212 -0.113 125.222 -0.116
202303 -0.327 127.348 -0.331
202306 -0.231 128.729 -0.231

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Paratek Pharmaceuticals  (FRA:N4CN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Paratek Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines